Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -238.1% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -243.1% | – | – | – |
| EPS Diluted | -0.39 | -0.55 | -0.38 | -0.36 |
| % Growth | 29.1% | -44.7% | -5.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |